dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Draft Monitoring and Evaluation Framework to end tuberculosis in WHO European Region 2021-2030

Sotsiaalministeerium · 25. veebruar 2020
Viit
1.4-2/568-1
Registreeritud
25. veebruar 2020
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Liisa Lents (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)
Lahendamise tähtaeg
28. veebruar 2020

Failid

  • 📎E-kiri.pdf534 KB
  • 📎Estonia.pdf264 KB
  • 📎List of ME indicators.pdf673 KB
  • 📎Monitoring and evaluation framework narative.pdf350 KB

Sisu (failidest)

Annex 1 Monitoring Framework WHO European Region Tuberculosis Action Plan 2021– 2030 The WHO European Region TB action plan 2021-2030 is supported with a Monitoring framework that enables a harmonized approach to monitor the progress towards Regional TB- AP 2021-2030 targets at both the national and regional levels and actions taken to put the End TB strategy into practice. Monitoring is not limited to tracking data on the TB surveillance and implementation of activities, but also includes evaluating the effectiveness and impact of interventions, consequently providing foundation for advocacy and policy development. The current document follows the structure of the previous Monitoring framework of the WHO European Region TB action plan 2016-2020, with the overall intention of keeping the limited number of indicators and maintaining details on calculations of each of the indicators used. Limiting the number of indicators is intended to avoid overburdening the framework and stay focused on issues that directly affect decision-making and provide measures of effectiveness. The framework consists of 28 indicators that allow monitoring of performance of the areas of interventions in the action plan. Ten were selected as core indicators for monitoring and reporting to the WHO Regional Committee for Europe (those highlighted in the list with E (European)). The list of indicators closely follows the structure of the action plan. Each area of intervention is reflected in the framework by one or more indicators, assessed by the task force to represent the most accurate measure of performance of the group of activities. The Monitoring framework includes indicators that allow oversight of progress towards achievement of regional targets: 1. Impact indicators that measure progress towards the three End TB Strategy and WHO European Region targets; 2. Outcome indicators that monitor broader changes in TB control enhanced as a result of a set of interventions; 3. Output indicators that monitor progress of specific interventions that measure policy environment, commitment and capacity among Member States. Indicator development was guided by principles which defined that the indicators should be: • Broad enough to reflect all aspects of the ambitious action plan; • Sufficiently specific to address critical markers of success; and • Concise, so as not to overburden national programmes. In addition, selection of indicators was harmonized with the End TB Strategy’s recommended top 10 global indicators, highlighted in the list with G (Global) and focusing on indicators that are collected regularly through the routine recording and reporting system. These indicators, while regional in scope, are designed to serve as a guide to the development or adjustment of comprehensive monitoring plans at country level. Baseline value, desired target, assessment frequency, monitoring mechanism and data source are defined for each indicator/group of indicators. The framework includes quantitative and qualitative indicators: if quantitative, numerators and denominators are listed; if qualitative, basic criteria of favorable assessment (Yes/No) are listed. Baseline levels in most cases were defined using information provided by each country through the WHO/European Centre for Disease Prevention and Control (ECDC) annual TB data collection process. This is standardized to the WHO recommended recording and reporting framework, has Region-wide coverage, is undertaken only once (therefore avoiding duplication of effort by countries and partners) and ensures a user-friendly mechanism for data collection. The absence of baseline information in a limited number of indicators from the full list might be explained by the unavailability of these data and/or questionable reliability of the information available. To prioritize the area of intervention, indicators will be measured according to the following layers: 18 high-priority countries to stop TB in the WHO European Region;1 European Union/European Economic Area countries; and WHO European Region level. Analysis by country will be performed to assess country-specific benchmarks, performance over time and the eventual achievement of all objectives. Most indicators will be monitored annually. In addition to the joint WHO/ECDC annual data collection, desk reviews will be performed at the beginning of implementation of the action plan and when full implementation is expected to monitor activities that are not reflected in the WHO/ECDC TB data collection form. In-depth assessment of reports from countries and external technical support will provide additional material to support the measurement of indicators. In the absence of these main sources of information, an interview with the national programme (or equivalent) will be undertaken to assess performance on interventions implemented as part of the action plan. Only data approved by Member States will be used in monitoring the action plan. The indicators outlined in the regional Monitoring framework should be integrated with national TB control programmes’ Monitoring and Evaluation (M&E) frameworks at country level. In addition to the indicators outlined in the regional framework, countries may also include additional indicators to monitor progress of national strategies, taking into account country-specific priorities. The full results of assessments of performance on interventions delivered through implementation of the action plan will be presented every second year via a joint WHO/ECDC report on TB surveillance and monitoring in Europe. The report will consist of analysis and interpretation of data based on the indicators and will include recommendations. Progress in action plan implementation will be reported every second year to the Regional Committee and monitoring reports will be presented to the meeting of national TB programme managers/country focal points that is open to stakeholders and civil society organizations involved in TB control in the Region. 1 18 high-priority countries for TB control in the WHO European Region: Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of Moldova, Romania, Russian Federation, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbekistan. Reference: Plan to Stop TB in 18 High-priority Countries in the WHO European Region, 2007–2015 (ISBN 978 92 890 7180 2) Saatja: EURO TB <[email protected]> Saadetud: 24.02.2020 18:48 Adressaat: Elen Ohov <[email protected]> Koopia: DARA, Masoud <[email protected]>; YEDILBAYEV, Askar <[email protected]>; KUCHUKHIDZE, Giorgi <[email protected]>; MULLABAYEV, Garif <[email protected]>; VYSHNEVSKA, Svitlana <[email protected]>; Triin Uusberg <[email protected]>; SM Info <[email protected]>; <[email protected]>; <[email protected]>; REINAP, Marge <[email protected]>; REINAP, Marge <[email protected]> Teema: Draft Monitoring and Evaluation Framework to end tuberculosis in WHO European Region 2021-2030 Manused: Estonia.pdf; List of ME indicators.pdf; Monitoring and evaluation framework narative.pdf Dear Ms. Ohov, Enclosed is the letter from Dr Masoud Dara, Coordinator, Communicable Diseases Division of Health Emergencies and Communicable Diseases, about the status of the Monitoring and Evaluation Framework to end tuberculosis in WHO European Region 2021-2030 for your kind consideration. Sincerely yours, Joint Tuberculosis, HIV and Hepatitis Programme (JTH) Division of Health Emergencies and Communicable Diseases (DEC) World Health Organization, Regional Office for Europe (WHO/Europe) UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark Tel: +45 4533 6827 or +45 4533 6609 ¦ Fax: +45 4533 7001 E-mail: [email protected]; Description of indicators, Tuberculosis action plan 2021-2030 Legend: • Three indicators are highlighted bold (1.B.5, 1.C.4 and 1.C.6). They measure the targets set in the region. • The 10 European core indicators are highlighted grey (including the 3 indicators above) • In red are the corresponding 10 core indicators developed by WHO Headquarters (see also MAF-TB appendix). 1. INTEGRATED, PATIENT-CENTRED CARE AND PREVENTION A Systematic screening of contacts and high-risk groups 1.A.1 Coverage of contacts with systematic screening for Numerator: Number of contacts of TB patients identified in the reporting year who active TB (G) were screened for TB* Denominator 1: Number of contacts of active TB patients identified in the reporting year Denominator 2: Estimated number of household contacts of TB patients in the reporting year ** *According to the national guidelines **For measuring the coverage of the contact investigation; source: United Nations, Department of Economic and Social Affairs, Population Division. Household Size and Composition Around the World. Global Top-10 indicator (6) Contact investigation coverage Number of contacts of people with bacteriologically confirmed TB who were evaluated for TB, divided by the number eligible, expressed as a percentage. B. Early diagnosis of all forms of tuberculosis and universal access to drug-susceptibility testing, including the use of rapid tests 1.B.1 Percentage of notified new and relapse TB patients Numerator: Number of new and relapse patients tested using a WHO-recommended tested using WHO-recommended rapid tests (G) rapid diagnostic (for example Xpert MTB/RIF) as the initial diagnostic test (regardless of test result) Denominator: Total number of new and relapse patients notified Global Top-10 indicator (4) Percentage of new and relapse TB patients tested using a WHO recommended rapid diagnostic (WRD) at the time of diagnosis Number of new and relapse TB patients tested using a WRD at the time of diagnosis, divided by the total number of new and relapse TB patients, expressed as a percentage. 1.B.2 DST coverage (%) among all pulmonary TB patients (G) Numerator: Number of patients with drug susceptibility test results for at least rifampicin among pulmonary TB patients* Denominator 1: Total number of pulmonary TB patients notified Denominator 2: Total number of bacteriologically confirmed pulmonary TB patients * DST coverage includes results from molecular tests (e.g. WHO recommended rapid diagnostic test) as well as conventional phenotypic DST results Global Top-10 indicator (7) Drug-susceptibility testing (DST) coverage for TB patients Number of TB patients with DST results for at least rifampicin, divided by the total number of notified (new and retreatment) cases in the same year, expressed as a percentage. DST coverage includes results from molecular (e.g. Xpert MTB/RIF) as well as conventional phenotypic DST results. 1.B.3 RR/MDR TB case detection rate (%) Numerator: Total number of bacteriologically confirmed pulmonary RR/MDR-TB patients notified Denominator: Total number of estimated RR/MDR-TB patients among notified pulmonary TB 1.B.4 TB case detection rate (%) Numerator: Total number of new and relapse TB patients notified Denominator: Total number of estimated new and relapse TB patients 1.B.5 TB notification rate per 100 000 population (E) Numerator: Total number of new and relapse TB patients notified Denominator: Population number/100 000 1.B.6 RR-MDR/TB notification rate per 100 000 population Numerator: Total number of bacteriologically confirmed RR-TB or MDR-TB patients notified Denominator: Population number/100 000 Equitable access to quality treatment and continuum of care for all people with tuberculosis, including drug-resistant tuberculosis; and patient C. support to facilitate treatment adherence 1.C.1 Percentage of patients starting first line TB treatment at Estimated percentage of patients that are receiving TB treatment at the ambulatory the outpatient healthcare level (E) (outpatient) level (%) among patients starting first-line TB treatment Additional indicator: Estimated percentage of patients that are receiving TB treatment at the ambulatory (outpatient) level (%) among patients starting second-line TB treatment 1.C.2 Percentage of notified RR/MDR TB patients enrolled in Numerator: Total number of RR/MDR TB patients enrolled into SLD treatment treatment (G) (E) Denominator: Total number of RR/MDR TB patients notified Global Top-10 indicator (1) TB treatment coverage Number of new and relapse cases that were notified and treated, divided by the estimated number of incident TB cases in the same year, expressed as a percentage. 1.C.3 Treatment success rate (%) among all new and relapse Numerator: New and relapse TB patients notified in a specified period who were TB patients (G) successfully treated Denominator: Total number of new and relapse TB patients notified in the same period Global Top-10 indicator (2) TB treatment success rate Percentage of notified TB patients who were successfully treated. The target is for drug-susceptible and drug-resistant TB combined, although outcomes should also be reported separately. 1.C.4 Treatment success rate (%) among the RR/MDR-TB Numerator: Number of bacteriologically confirmed RR/MDR TB patients during the treatment cohort (G) (E) specified period that were successfully treated Denominator: Number of bacteriologically confirmed RR/MDR TB patients that started on a prescribed TB treatment regimen during the specified period. Global Top-10 indicator (2) TB treatment success rate Percentage of notified TB patients who were successfully treated. The target is for drug-susceptible and drug-resistant TB combined, although outcomes should also be reported separately. 1.C.5 Treatment success rate (%) among the XDR-TB Numerator: Number of bacteriologically confirmed XDR-TB patients during the treatment cohort (G) (E) specified period that were successfully treated Denominator: Number of bacteriologically confirmed XDR-TB patients that started on a prescribed TB treatment regimen during the specified period. Global Top-10 indicator (2) TB treatment success rate Percentage of notified TB patients who were successfully treated. The target is for drug-susceptible and drug-resistant TB combined, although outcomes should also be reported separately. 1.C.6 TB mortality rate per 100 000 population (G) (E) Numerator: Estimated number of TB deaths (ICD A15-19; B90) (from VRS) Denominator: Total number of population/100 000 Global Top-10 indicator (10) Case fatality ratio (CFR) Number of TB deaths divided by estimated number of incident cases in the same years, expressed as a percentage. D. Collaborative tuberculosis/HIV activities, and management of relevant comorbidities 1.D.1 TB/HIV case-detection rate (%) Numerator: Total number of notified HIV co-infected TB patients among new and relapse TB patients in a specified period Denominator: Total number of estimated TB/HIV co-infected patients among new and relapse TB patients 1.D.2 HIV testing coverage (%) (G) (E) Numerator: Total number of notified new and relapse TB patients in a specified period with reported HIV status Denominator: Total number of notified new and relapse TB patients in the specified period Global Top-10 indicator (9) Documentation of HIV status among TB patients Number of new and relapse TB patients with documented HIV status, divided by the number of new and relapse TB patients notified in the same year, expressed as a percentage. 1.D.3 Percentage of HIV positives among new and relapse TB Numerator: Total number of notified new and relapse TB patients in a specified period patients with documented test results who are HIV positive Denominator: Total number of notified new and relapse TB patients in the specified period with documented HIV test results 1.D.4 ART coverage (%) among TB/HIV patients Numerator: Total number of notified new and relapse TB/HIV patients in a specified period who are enrolled in antiretroviral therapy (ART)* Denominator: Total number of notified new and relapse TB patients in the specified period who are HIV positive * Within 8 weeks of starting TB treatment E. Management of latent tuberculosis infection and preventive treatment of persons at high risk, and vaccination against tuberculosis 1.E.1 LTBI treatment enrolment rate (%) among PLHIV (G) Numerator: Total number of new HIV patients enrolled in LTBI treatment in a specified period Denominator: Total number of new HIV patients eligible for LTBI treatment in the specified period Global Top-10 indicator (5) Latent TB infection (LTBI) treatment coverage Number of people living with HIV newly enrolled in HIV care and the number of children aged <5 years who are household contacts of cases started on LTBI treatment, divided by the number eligible for treatment, expressed as a percentage (separately for each of the two groups). 1.E.2 LTBI treatment coverage (%) in childhood TB contacts Numerator: Total number of child TB contacts age <5 years enrolled in LTBI treatment aged under 5 years (G) (E) in the specified period Denominator: Estimated number of child TB contacts eligible for LTBI treatment in the specified period Global Top-10 indicator (5) Latent TB infection (LTBI) treatment coverage Number of people living with HIV newly enrolled in HIV care and the number of children aged <5 years who are household contacts of cases started on LTBI treatment, divided by the number eligible for treatment, expressed as a percentage (separately for each of the two groups). 2. BOLD POLICIES AND SUPPORTIVE SYSTEMS A. Political commitment with adequate resources, including universal health coverage policy 2.A.1 Number of Members States that have a TB control Method of measurement: review (53 Member States, this includes the example of TB strategy document publicly available that includes control measures integrated in overall strategy or standalone document) targets for reduction in TB mortality and incidence in line with the regional and global targets set in the resolution WHA67.1 and EUR/RC70/RX (E) B. Health systems strengthening in all functions, including well-aligned financing mechanisms for tuberculosis and human resources 2.B.1 Percentage of TB-affected households that experience Source: TB catastrophic cost surveys catastrophic costs due to TB (G) (E) Global Top-10 indicator (3) Percentage of TB-affected households that experience catastrophic costs due to TB Number of people treated for TB (and their households) who incur catastrophic costs (direct and indirect combined), divided by the total number of people treated for TB. C. Regulatory frameworks for case-based surveillance, strengthening vital registration, quality and rational use of medicines, and pharmacovigilence 2.C.1 Treatment coverage with modified Shorter all-oral Numerator: Number of TB patients treated with modified Shorter all-oral Treatment Treatment Regimens (mSTR) (G) Regimens (mSTR) Denominator: Number of notified patients eligible for treatment with modified Shorter all-oral Treatment Regimens (mSTR) Global Top-10 indicator (8) Treatment coverage, new TB drugs Number of TB patients treated with regimens that include new (endorsed after 2010) TB drugs, divided by the number of notified patients eligible for treatment with new TB drugs, expressed as a percentage. E. Community systems and civil society engagement 2.E.1 Number of Member States with adopted standards and Number of Member States with adopted standards and operational procedures for civil operational procedures for civil society organizations society organizations (CSOs) in the provision of psycho-social support services to ensure (CSOs) in the provision of psycho-social support services treatment adherence for people with TB to ensure treatment adherence for people with TB 2.E.2 Number of Member States with adopted procedures of Number of Member States with adopted procedures of subcontracting mechanisms subcontracting mechanisms under the state funds or under the state funds or other relevant funding mechanisms for CSOs in the provision of other relevant funding mechanisms for CSOs in the psycho-social support and active case-finding services for people with TB provision of psycho-social support and active case- finding services for people with TB 2.E.3 Proportion of people with TB found through active case- Numerator: Number of people with TB from key affected population referred by finding activities implemented through CSOs community volunteers/NGOs for TB diagnosis and treatment Denominator: Total number of people with TB notified during the same period 2.E.4 Proportion of people with TB who started TB treatment Numerator: number of people with TB who started TB treatment and who received any and who received any form of treatment adherence form of treatment adherence support from CSO (including psycho-social support) support from CSO (including psycho-social support) Denominator: Total number of people with TB started treatment during the same period F. Social protection, poverty alleviation and actions on other determinants of tuberculosis, such as migration and prisons 2.F.1 Treatment success rate (%) of new and relapse TB Numerator: New and relapse TB patients notified in a specified period that were patients among prisoners successfully treated in prisons Denominator: Total number of new and relapse TB patients notified in the same period in prisons 3. INTENSIFIED RESEARCH AND INNOVATION A. Discovery, development and rapid uptake of new tools, interventions and strategies 3.A.1 Number of Member States with a standing alone national TB research agenda or research priorities integrated in the national TB strategic plans or relevant policies. WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ WELTGESUNDHEITSORGANISATION Date: 24 February 2020 ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ REGIONAL OFFICE FOR EUROPE Ms. Elen Ohov BUREAU RÉGIONAL DE L’EUROPE REGIONALBÜROFÜREUROPA Adviser ЕВРОПЕЙСКОЕРЕГИОНАЛЬНОЕБЮРО European Union Affairs and International Co- Head office: operation Department UN City, Marmorvej 51, Ministry of Social Affairs DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1 Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01 Email: [email protected] Tallinn 10122 Website: http://www.euro.who.int Estonia Our reference: Yourreference: Notre référence: Votre référence: UnserZeichen: IhrZeichen: См. нашномер: НаВашномер: Draft Monitoring and Evaluation Framework to end tuberculosis in WHO European Region 2021-2030 Dear Ms. Ohov, In 2015, the 65th WHO Regional Committee for Europe endorsed the Tuberculosis Action Plan 2016- 2020, in line with the Global End TB Strategy. In a follow up to the resolution EUR/RC65/17, the final report of implementation of the Action Plan is to be submitted to 70th Regional Committee in September 2020. The secretariat is finalizing the mentioned report which will be submitted for Member States’ review and endorsement along with a suggestion to extend the validity of Tuberculosis Action Plan with a vision to end TB epidemic, with zero affected families facing catastrophic costs due to TB by 2030. To monitor the progress and in line with the commitments articulated in the UN High Level Political Declaration, a Monitoring and Evaluation Framework 2021-2030 with new indicators and targets are prepared. These indicators, while regional in scope, are designed to serve as a guide to the development or adjustment of comprehensive monitoring plans at country level. The process of development of this framework, included several meetings and consultations of WHO Regional Office for Europe with experts working in the monitoring and evaluation field: - On 28-30 August 2019, the WHO Regional Office for Europe organized a meeting of the WHO consultants involved in the TB surveillance and response monitoring related activities in the Region. As an output of this meeting, an initial draft of the new framework with description of indicators was developed. - As a next step, in October 2019, the WHO Regional Office for Europe established a Task Force, representing different partners from international, governmental and non-governmental organizations, including national tuberculosis programmes, people affected and civil society organizations working in the field of Tuberculosis to finalize Monitoring and Evaluation framework of the TB Action Plan for the WHO European Region. - The Task Force held regular online meetings followed by several rounds of revisions of the list and description of indicators. Monitoring and Evaluation framework was finalized in January 2020. UN City,Marmorvej 51 Tel.: +45 45 33 70 00 Email: [email protected] DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int Denmark The Monitoring and Evaluation framework consists of 28 indicators that allow monitoring of performance of the areas of interventions in the Action Plan. Ten were selected as core indicators for monitoring and reporting to the WHO Regional Committee for Europe. The list of indicators closely follows the structure of the action plan. Each area of intervention is reflected in the framework by one or more indicators, assessed by the task force to represent the most accurate measure of performance of the group of activities. We have the pleasure to share with you the mentioned draft Monitoring and Evaluation framework for review by your national experts by 28 February 2020. Your experts may contact Dr Giorgi Kuchukhidze ([email protected]) should they have any questions or need any clarification. Yours sincerely, Dr Masoud Dara Coordinator, Communicable Diseases Division of Health Emergencies and Communicable Diseases WHO Regional Office for Europe Copy for information to: Ms Triin Uusberg Head European and International Coordination Department Ministry of Social Affairs Suur-Ameerika 1 Tallinn 10129, Estonia H.E. Ms Katrin Saarsalu-Layachi Ambassador Extraordinary and Plenipotentiary, Permanent Representative Permanent Mission of the Republic of Estonia to the United Nations Office and other international organizations in Geneva Chemin du Petit-Saconnex 28A Genève CH-1209, Switzerland H.E. Mr Märt Volmer Ambassador Extraordinary and Plenipotentiary Embassy of the Republic of Estonia Frederiksgade 19, 4th floor Copenhagen K 1265, Denmark Ms Marge Reinap Head of WHO Office WHO Country Office, Estonia Paldiski Road 81 Tallinn 10617, Estonia –2–
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel